You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Novo Nordisk Articles
Popular Novo Nordisk Articles
Highly Recommended Novo Nordisk Articles
Long-Acting Insulin Will Compete Against Lantus
On October 8, 2003, Novo Nordisk announced that it had received an “Approvable Letter” from the U.S. Food and Drug Administration (FDA) for insulin detemir, its long-acting insulin analog.
At present, Lantus (insulin glargine), manufactured by Aventis, is the only long-acting insulin analog on the market.
In the letter, the FDA requests that Novo Nordisk address certain clinical issues and provide additional information before U.S. marketing approval can be granted. The company says that it is working with the FDA to clarify and resolve outstanding issues.
Novo Nordisk expects to provide an update of the timeline for U.S. approval when it releases its 2003 financial statement on February 5, 2004 pending completion of consultations with the FDA.
-October 8,2003, Novo Nordisk Stock Exchange announcement.
Categories: Food, Government & Policy, Insulin, Lantus, Novo Nordisk, Type 1 Issues
0 comments -
Feb 1, 2004
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.




Email to a Friend
Send a link to this page to your friends and colleagues.